Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel Olde Rikkert

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2017
Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markersRon L H Handels, Stephanie J B Vos, Milica G Kramberger, et al.
Alzheimer'S Research & Therapy|December 30, 2017
Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive declineIsabelle Bos, Frans R Verhey, Inez H G B Ramakers, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 12, 2014
The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?Flora H Duits, Charlotte E Teunissen, Femke H Bouwman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 6, 2019
Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotypeLisa Vermunt, Sietske A M Sikkes, Ardo van den Hout, et al.
BMJ Open|July 21, 2016
European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flowOlga Meulenbroek, Sarah O'Dwyer, Daan de Jong, et al.
Epigenomics|June 26, 2015
DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohortsLeonidas Chouliaras, Gunter Kenis, Pieter Jelle Visser, et al.
Gerontology|February 8, 2023
Supporting Resilience of Older Adults with Cognitive Decline Requires a Multi-Level System ApproachGeeske Peeters, Almar Kok, Simone R de Bruin, et al.
Journal of the American Geriatrics Society|December 23, 2011
Do instrumental activities of daily living predict dementia at 1- and 2-year follow-up? Findings from the Development of Screening guidelines and diagnostic Criteria for Predementia Alzheimer's disease studySietske A M Sikkes, Pieter Jelle Visser, Dirk L Knol, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 17, 2020
Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer's disease scale: development and results from a mapping studyInes Rombach, Marvi Iftikhar, Gurleen S Jhuti, et al.
Journal of Alzheimer'S Disease : JAD|April 1, 2016
Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective CohortRon L H Handels, Manuela A Joore, Stephanie J B Vos, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2017
Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markersRon L H Handels, Stephanie J B Vos, Milica G Kramberger, et al.
Alzheimer'S Research & Therapy|December 30, 2017
Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive declineIsabelle Bos, Frans R Verhey, Inez H G B Ramakers, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 12, 2014
The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?Flora H Duits, Charlotte E Teunissen, Femke H Bouwman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 6, 2019
Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotypeLisa Vermunt, Sietske A M Sikkes, Ardo van den Hout, et al.
BMJ Open|July 21, 2016
European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flowOlga Meulenbroek, Sarah O'Dwyer, Daan de Jong, et al.
Epigenomics|June 26, 2015
DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohortsLeonidas Chouliaras, Gunter Kenis, Pieter Jelle Visser, et al.
Gerontology|February 8, 2023
Supporting Resilience of Older Adults with Cognitive Decline Requires a Multi-Level System ApproachGeeske Peeters, Almar Kok, Simone R de Bruin, et al.
Journal of the American Geriatrics Society|December 23, 2011
Do instrumental activities of daily living predict dementia at 1- and 2-year follow-up? Findings from the Development of Screening guidelines and diagnostic Criteria for Predementia Alzheimer's disease studySietske A M Sikkes, Pieter Jelle Visser, Dirk L Knol, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 17, 2020
Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer's disease scale: development and results from a mapping studyInes Rombach, Marvi Iftikhar, Gurleen S Jhuti, et al.
Journal of Alzheimer'S Disease : JAD|April 1, 2016
Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective CohortRon L H Handels, Manuela A Joore, Stephanie J B Vos, et al.
Pageof 10